Ibrance for pancreatic and cholangiocarcinoma – pro
There is some preliminary suggestiosn fo efficacy fo Ibrance for chlangiocarcinoma, but very preliminary. Most recently, results from ASCO’s Targeted Agent and Profiling Utilization Registry (TAPUR) study have demonstrated that single-agent palbociclib has no meaningful clinical activity in patients with CDKN2A-mutated or -deleted advanced pancreatic adenocarcinoma and cholangiocarcinoma. These findings were published by Baghdadi et al in JCO Precision Oncology.
Tareq Al Baghdadi et al,Palbociclib in Patients With Pancreatic and Biliary Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study. DOI: 10.1200/PO.19.00124 JCO Precision Oncology – published online August 14, 2019
G. SItticumarcharee, HepatologyVolume70, Issue5 November 2019 Pages 1614-1630